Funder
National Institutes of Health
Reference10 articles.
1. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled, multicentre trial;Höglinger;Lancet Neurol,2021
2. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK;Nath;Brain,2001
3. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated;Robinson;Brain,2018
4. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo;Yanamandra;Neuron,2013
5. Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer's disease and other tauopathies;West;J Prev Alzheimers Dis,2017
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献